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Abstract
Background:  Despite the presence of a plethora of publications on the prevention of
postoperative nausea and vomiting (PONV) only little is known how to treat established symptoms.
Besides the high effort of performing these efficacy trials (much more patients must give their
consent than are actually included in a study) and ethical concerns, little is known about the rate
of re-occurring PONV/vomiting after placebo. As a consequence investigators will have difficulties
defining a clinically relevant effect for the new treatment which is crucial for any planning. A
quantitative systematic review was performed in order to provide more reliable estimates of the
incidence of re-occurring PONV/vomiting after placebo and to help investigators defining a clinically
relevant treatment effect.
Methods: A systematic search of the literature was performed using an extended search strategy
of a previous review. Data on the recurrence of PONV (any nausea or emetic symptom) and
vomiting (retching or vomiting) was extracted from published reports treating PONV with placebo
and unpublished results from two observational trials where no treatment was given. A nonlinear
random effects model was used to calculate estimates of the recurrence of symptoms and their
95%-confidence intervals (95%-CI).
Results: A total of 29 trials (including the unpublished data) were eligible for the calculations.
Depending on the length of observation after administering placebo or no treatment the
recurrence rate of PONV was between 65% (95%-CI: 53%...75%) and 84% (95%-CI: 73%...91%) and
that of vomiting was between 65% (95%-CI: 44%...81%) and 78% (95%-CI: 59%...90%).
Conclusion: Almost all trials showed a considerable and consistently high rate of recurrence of
emetic symptoms after placebo highlighting the need for a consequent antiemetic treatment. Future
(placebo) controlled efficacy trials may use the presented empirical estimates for defining clinically
relevant effects and for statistical power considerations.
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Background
Postoperative nausea and vomiting (PONV) are frequent
adverse events after anaesthesia. In western countries
about 10% of the population undergoes a surgical proce-
dure every year. Assuming that still a quarter of all patients
suffer from PONV, more than 18 million patients are nau-
seated or vomit after their surgery in Europe. Although
these symptoms are self-limiting and rarely cause major
medical problems they are distressing for the patient and
may have negative economic implications, e.g. by causing
unanticipated hospital admission in surgical outpatients
due to intractable vomiting.
There is some evidence that patients at a considerable
high risk for developing PONV can benefit from prophy-
lactic antiemetic treatment [1]. However, applying the
same approach for patients at a low or moderate risk is not
unequivocally supported and fails to improve patient sat-
isfaction compared to symptomatic treatment in the post-
operative recovery room [1]. The main reason for the poor
results of any conventional antiemetic strategy is that the
number of patients that need to be treated prophylacti-
cally highly depends on the baseline risk of the popula-
tion. For instance, if high risk patients with an expected
risk for PONV of 80% are treated with an antiemetic inter-
vention that halves this baseline risk then the achieved
absolute risk reduction of 40% translates into a NNT of
2.5 that without doubt is highly efficient. In a population
with a low risk for PONV (e.g. 10%), however, the same
intervention will lead to a (disappointing) 5% absolute
risk reduction and the NNT is 20.
This simple calculation demonstrates that routine
antiemetic prophylaxis is not indicated from a medical
(potential side effects of antiemetics) and economic point
of view (increased costs). However, the optimal threshold
(percentage of expected risk) at which prophylaxis is indi-
cated cannot be quantified since several other issues mod-
ify the perceived risk. Thus, a recent consensus conference
did not give a clear recommendation regarding this point
[2].
The situation is further complicated by the lack of a clini-
cally satisfying solution to predict PONV. The accuracy of
prediction using one of the available simple scoring sys-
tems [3,4] is at best increased to a discriminating power of
about 70% compared to a random guess with a pre-hoc
accuracy of 50% [5,6]. Furthermore, even if there was a
perfect prognostic tool, theoretical consideration using
computer simulation of the effectiveness and efficacy of
various prophylactic antiemetic strategies could not iden-
tify one optimal approach since the "most effective" or
"most efficient" strategy strongly depends on the distribu-
tion of patients in a given institution [7]. As a conse-
quence, clinical strategies to deal with PONV in the
postanaesthetic care unit vary widely between different
institutions [8].
An alternative to administering prophylactic antiemetics
is to treat established nausea and vomiting postopera-
tively. This strategy has been shown to be more cost-effec-
tive than prophylaxis [9]. However, a systematic review
evaluating studies on treatment of PONV stated that there
is a discrepancy between the plethora of trials on preven-
tion of PONV and the paucity of trials on the treatment of
established symptoms [10]. There are several reasons for
this obvious disparity. First, manufacturers of antiemetic
drugs have more commercial interest in prophylaxis strat-
egies which may be the reason for the complete lack of tri-
als with older classic antiemetics when treatment of
established PONV is concerned. Second, in the absence of
evidence in favour of a (gold) standard for treatment of
established PONV, one will have to utilize placebo con-
trol groups. Since ethics committees have the duty to bal-
ance between the patients' interest and the scientific
benefit, it can be speculated that they will be reluctant to
approve such trials since there is good evidence from sev-
eral surveys of in- and outpatients [11,12] that postopera-
tive nausea and vomiting is as unpleasant as postoperative
pain. The problems related to placebo treatment are sup-
ported by thorough criticism of trialists and sponsoring
companies performing placebo-controlled trials in the
prophylaxis of postoperative nausea and vomiting [13,14]
– trials that all provided sufficient antiemetic rescue med-
ications for all participants! Third, and most importantly,
therapeutic trials are more difficult to perform. Of the
total number of patients giving informed consent to par-
ticipate in such a trial, only about 20–30% (at "best") can
be expected to be randomized due to the fact that the
majority of patients never suffer from PONV. In addition,
the number of patients that are willing to participate in a
placebo-controlled PONV-trial will probably be rather
low, especially in patients with a high risk to develop
emetic symptoms, e.g. due to previous PONV. Further-
more, study protocols will have to be very precise concern-
ing the inclusion criteria and the proceedings in case of
adverse events (e.g. because of the necessary definitions
when to administer a rescue antiemetic, etc.) and these
regulations will probably result in artificial circumstances
that might not be representative of a "real world" situa-
tion and thus such trials might lack external validity.
Besides all these obstacles, there is an obvious need for tri-
als showing efficacy of an antiemetic for the treatment of
PONV-symptoms prior to its routine application. In the
absence of an accepted (gold) standard treatment [15],
one may have to use placebo control treatment arms. Any
efficacy consideration in terms of clinically relevant treat-
ment effects, however, implies some knowledge about the
incidence of an event with placebo treatment. ConfrontedBMC Anesthesiology 2006, 6:14 http://www.biomedcentral.com/1471-2253/6/14
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with this dilemma we decided to update a recent review
on trials on the efficacy of therapeutic antiemetic interven-
tions [10]. This material was amended by unpublished
data that were collected in order to validate a variety of
different risk scores to predict the occurrence of PONV [5]
and to train and validate an artificial neural network for
the same purpose [16].
Thus, the aim of this study was twofold. First, it was set up
to provide a more reliable incidence estimate for the
recurrence of emetic symptoms following an initial emetic
episode and after receiving placebo during the early post-
operative period (e.g. in the recovery room). Secondly,
these data were to propose the choice of clinically relevant
effects for future trials studying antiemetic interventions
for the treatment of PONV. Based on these data we will
also discuss the possibility to perform PONV treatment
trials with no placebo comparator group by using a virtual
benchmark for such trials.
Methods
In order to determine a more reliable incidence estimate
for patients with reappearance of nausea or vomiting after
a first episode of these symptoms in the recovery room, a
systematic review of trials was performed that docu-
mented the rate of recurrence of PONV after giving pla-
cebo or no treatment. For data retrieval and extraction we
updated a previous systematic review of Kazemi-Kjellberg
et al. published in 2000 [10].
We used the search strategies of this systematic review and
created modified algorithms with the help of a librarian
(S.F.). We used the following search terms or roots for
inclusion "postoperative OR postsurg*", "nausea OR
vomit* OR emesis OR emetic OR retch*", "treatment OR
control" and the phrases "chemotherapy OR radiotherapy
OR prophylaxis or prevention" for exclusion. There was
no restriction to placebo-controlled trials. Given this strat-
egy, we searched Medline, Old Medline (reaching back to
1950 – 1959 Current List of Medical Literature), EMBASE,
and the Cochrane Controlled Trials register (CENTRAL)
aiming at all trials that provide numbers about the inci-
dence of patients that suffer from any emetic sequelae
after a first episode of PONV during the early postopera-
tive period. The date of the last literature search was 16th
December 2005. Additionally we hand-searched the refer-
ences of all matching papers and review articles for addi-
tional reports but did not contact the pharmaceutical
industry for further unpublished data. In contrary to the
first systematic review [10] we did not exclude articles that
reported the incidence of PONV instead of two distinct
incidences for nausea and vomiting. For the given study,
these PONV incidences were equated with nausea since
results from almost all trials suggests that vomiting with-
out prodromal nausea is extremely rare. Thus, "PONV"
was defined as any nausea or vomiting or retching (with
or without a rescue medication at this stage) in the post-
operative period and "vomiting" as retching or vomiting
postoperatively. Most of the identified trials did not use
an intraoperative antiemetic prophylaxis and do not
report risk factors for PONV present in the patients who
then suffered from nausea or vomiting in the recovery
room. However, studies were not excluded in case such
explicit information were lacking. The data from the iden-
tified reports were independently extracted by two
researchers. The Oxford-score (Jadad-score) was assessed
for each study [17]. In the case of disagreement between
the two results a referee (L.E.) was consulted to solve the
disagreement. The analysis was performed according to
the recommendations of the QUORUM-statement [18].
Re-analyses of two observational trials
Results of two observational surveys on the occurrence of
PONV [5,16] were re-analyzed. Both studies covering a
total of 3608 patients had been approved by the local eth-
ics committee and informed consent was obtained from
each patient. Both trials were designed to evaluate poten-
tial risk factors for PONV. Due to the observational char-
acter of the surveys, the type and the length of surgery and
anaesthesia were recorded but no efforts were made to
modify the drugs or techniques used. Both were chosen
according to local standards at the discretion of the
attending anaesthetist. Of all the investigated patients
only those presenting nausea and/or vomiting in the
recovery room were analyzed for the rate of recurrence of
these symptoms within the first 24 hours after emergence
from anaesthesia. Nausea was defined as an active com-
plaint of the patient that lasted at least 5 minutes. Retch-
ing was rated as vomiting (emetic episode). Patients with
these symptoms were treated at the discretion of the
attending nursing staff. Again, antiemetic therapy was not
standardized and comprised mainly of dopamine antago-
nists (metoclopramide and droperidol) and to a lower
extent also antihistamines (e.g. dimenhydrinate), since
newer antiemetics like 5-HT3-antagonists were not availa-
ble for postoperative treatment at that time the data were
recorded.
After discharge from the post-anaesthesia care unit
(PACU), patients were visited on the ward 6–8 hours and
24–26 hours postoperatively by a specially trained
observer. Both, the patients and the nursing staff, were
asked whether nausea and/or an emetic episode had
occurred. Additionally, the medical records were screened
in order not to miss symptoms of PONV in a patient.
Statistical analysis
It is evident that the incidence of PONV is highly depend-
ent on the observational interval [19]. As the different
studies applied heterogeneous follow-up periods forBMC Anesthesiology 2006, 6:14 http://www.biomedcentral.com/1471-2253/6/14
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ascertaining PONV and vomiting, it was decided to do an
a priori classification of the studies investigating adults
(0–1 h, 0–2 h, 0–6 h, and 0–24 h of postoperative follow-
up). For each follow-up group separate pooled incidence
estimates were obtained. Note that single studies may
appear up to four times in different groups i.e. one study
may have presented data for two follow-up intervals for
both PONV and vomiting (see details in table 1). Further-
more, the number of studies within each group can be
considerably small. In order to deal with this problem, a
nonlinear random effects model (NLMIXED in SAS Ver-
sion 8.02) was applied to obtain pooled incidence esti-
mates and the respective 95% confidence intervals as
recommended by Kuss [20]. The analyses were done twice
including/excluding the data from the two observational
trials to investigate whether the observational character of
these studies had an effect on the estimates. For simple
interval estimates of rates the classical method of Clopper
and Pearson [21] was applied.
Results
Systematic review of the literature
Using several search strategies we identified 163 poten-
tially relevant papers. After reviewing the abstracts of these
reports by two independent researchers (L.E. and P.K.) 63
articles were intensively screened as full texts. Of these 35
had to be excluded for the following reasons:
• lack of a placebo or no treatment group: n = 27
• overt double publication (see reference [10] for details):
n = 3
• prophylaxis and treatment not separable: n = 2
• studies performed in paediatric patients n = 2
• no information on PONV or vomiting provided (only
need for antiemetics): n = 1
Finally, within the remaining 28 publications, placebo or
no treatment was used in at least some of the patients pre-
senting with emetic symptoms in the early postoperative
period and were used for the calculation of the pooled
incidences of PONV and vomiting reappearance. Of these,
ten trials had an Oxford-score of 4 or 5 (out of 5 possible).
The lowest score was 2 the greatest 5 with a median of 3.
All identified studies had at least one active comparator
group (tropisetron, ondansetron, dolasetron, granisetron,
propofol, haloperidol, droperidol, domperidone, meto-
clopramide, alizapride, tiapride, and isopropyl alcohol for
inhalation). All trails were placebo controlled. The main
findings of the extracted papers are listed in table 1.
The unpublished results of the two observational trials
[5,16] are listed at the end of table 1. In the latter a total
of 3608 adult patients were observed prospectively. Dur-
ing the stay in the recovery room (mean duration of stay:
116 minutes) 584 (16%) of them developed nausea or
vomiting. Of these 380 patients were immediately treated
with a broad variety of antiemetic interventions. The
remaining 204 patients (35%) did not receive an
antiemetic drug. Reasons for the decision not to adminis-
ter an antiemetic was spontaneous relief of symptoms in
most of the cases (e.g. after an episode of vomiting) or
presence of contraindications against antiemetic drugs
that were commonly used during the time the study was
performed. Of the 204 patients who did not receive an
antiemetic after a first episode of PONV, 128 (63%) devel-
oped further emetic sequelae during their stay at the
recovery room and were subsequently treated with an
antiemetic. Of the remaining 76 patients discharged to the
ward without antiemetic treatment, 47 suffered from
PONV within the 24 hours observation period. Thus a
total of 175 (= 128+47) of the 204 patients (86%; 95%-
CI: 80%...90%) had reappearance of emetic symptoms
after not receiving no treatment. Their data was included
in the pooled analysis of the 0–24 hour period.
Figures 1 and 2 display the rate of recurrence of PONV and
vomiting respectively as reported by the original trials (y-
axis) depending on the time period of the observations (x-
axis). The number of patients investigated in these trials is
indicated by the size of the circular area whereas the
"quality" of the reporting (Jadad-score) is coded by shad-
ing.
The pooled estimates of the rate of recurrence after pla-
cebo comprise data from 28 trials. Depending on the
observation interval and the outcome criteria (PONV ver-
sus vomiting – regardless whether treated or not treated at
this stage) data of between 4 and 10 reports were used for
an analysis (table 2, figure 3). As expected, except for the
results of the 0–1 hour interval, an increasing incidence of
PONV-sequelae for both the pooled PONV and vomiting
estimates can be observed. Furthermore, the incidence of
PONV which comprises nausea and vomiting is higher
than the incidence of vomiting alone. However, the
respective 95% confidence intervals are rather wide rang-
ing between 51% and 92% for PONV and between 44%
and 90% for vomiting (irrespective of the time interval).
This is a result of the limited number of studies and the
lack of trials with large sample size within each investi-
gated time interval.
If, despite this variability, one wants to give recommenda-
tions for clinically relevant effects that can be considered
of interest for antiemetic trials studying the treatment of
PONV, one may consider two scenarios using the lowerB
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Table 1: Success rates of placebo or no treatment after a first emetic episode postoperatively.
Reference Oxford
-scale 
(R/B/D)
type of surgery/
patients
entry criteria recurrent 
PONV 
after ... 
hours
n/N recurrent 
vomiting 
after ... 
hours
n/N recurrent 
PONV 
after ... 
hours
n/N recurrent 
vomiting 
after ... 
hours
n/N
Alon, 1998 [28] 2/2/1 various patients, experiencing nausea lasting > 10 min and/
or emesis within 2 h after recovery from general 
anaesthesia
4 37/77 4 37/77 24 51/77 24 55/77
Anderson, 2004 [29] 1/1/0 various, outpatients patients, spontaneously reporting nausea in the 
PACU
26 / 1 2
Barton, 1975 [30] 2/1/0 various patients, developing nausea/vomiting in the 
recovery period
1 15/25 1 12/26 3* 24/30 3* 21/30
Bodner, 1991 [31] 1/1/0 laparoscopy, female 
outpatients
patients, complaining of persisting nausea (lasting 
>10 min) and/or experienced at least 2 episodes 
of emesis/retching
2 33/36
Boghaert, 1980 [32] 1/1/1 various vomiting postoperatively 1 33/44 6 37/44
Bonica, 1958 [33] 1/1/1 various 0.5 186/272
Borgeat, 1992 [34] 1/1/0 various patients, exhibiting major or severe nausea with 
vomiting
0.02 17/26 0,5 19/26
Diemunsch, 1997 [35] 1/1/0 various, primary 
gynaecological 
surgery
reporting nausea lasting 10 min or one emetic 
episode within 2 h in PACU
8 63/71 24 63/71
Diemunsch, 1999 [36] 1/1/0 abdominal or vaginal 
oophrectomy
experience of nausea and/or vomiting within 6 h 
of surgical recovery
6 16/18 6 14/18 24 18/18 24 17/18
Du Pen, 1992 [37] 1/1/1 primary 
gynaecological, 
outpatients
experience of nausea and/or vomiting within 2 h in 
the PACU
2 90/129 24 110/129
Fragen, 1978 [38] 2/0/1 gynaecologic surgical 
procedures
retching or vomiting in the immediate 
postoperative period
2 26/30 2 18/30 4 29/30 4 29/30
Fujii, 2004 [26] 2/2/1 laparoscopic 
cholecystectomy
experience of nausea lasting more than 10 min or 
retching or vomiting within 3 h after recovery
24 10/20 24 4/20
Gan, 1999 [39] ambulatory surgery significant nausea or vomiting within 1 h of arrival 
in the recovery room
2 18/23 2 13/23
Harper, 1998 [40] 2/2/1 laparoscopic 
gynaecological 
surgery
complaining of nausea and/or vomiting and 
requesting antiemetic treatment in the recovery 
room
1,5 2/12 3 9/12 3 6/12
Kauste, 1986 [41] 1/1/0 elective orthopaedic 
surgery
complains of nausea or retched or vomiting of any 
severity
6 22/36 24 30/36 24 24/36
Khalil, 1996 [42] 2/2/1 paediatric surgery, 
outpatients
experience of 2 emetic episodes within 2 h of 
discontinuation of nitrous oxygen
2 120/183 24 149/179B
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Korttila, 1979 [43] 1/1/0 orthopaedic surgery complains of nausea or retched or vomitinf of any 
severity
24 18/40
Kovac, 1997 [44] 2/1/0 various, outpatients postoperative nausea or vomiting within 2 h of 
arrival in the PACU
2 88/121 24 115/121 24 108/121
Kovac, 1999 [45] 2/1/1 various, outpatients experience of PONV or requesting antiemetic 
therapy within 2 h of the end of anaesthesia
2 122/214 24 145/214
Larijani, 1991 [46] 2/1/0 orthopaedic/
gynaecologic surgery
complaining of nausea or having a vomiting 
episode within 2 h of arrival in the recovery room
4 13/18 4 13/18
Lobera, 1981 [47] 1/1/0 breast surgery presenting nausea and/or vomiting 0.33 38/60
Loeser, 1979 [48] 1/1/0 n/a one or more episodes of vomiting in the recovery 
room
2 11/16
Polati, 1997 [49] 2/2/1 gynaecologic surgery experience of persistent nausea with at least one 
emetic episode within 4 h of recovery
1 39/60 48 53/60
Rung, 1997 [50] 2/2/1 orthopaedic/
gynaecologic surgery
experience of nausea and/or emesis and request 
of an antiemetic at any time after the start of 
opioid administration
6 27/32 24 27/32
Scuderi, 1993 [51] 2/1/0 outpatients if symptomatic treatment for persistent nausea or 
vomiting was necessary
2* 26/55
Stockman, 1978 [52] 1/1/0 various patients, who had a sufficient degree of 
postoperative nausea and/or vomiting to warrant 
antiemetic therapy
1 12/21
Taylor, 1997 [53] 2/1/0 gynaecological 
surgery
patients, who developed PONV within 4 hours of 
the end of surgery
6 111/133 6 98/133 24 116/133 24 107/133
van Leeuwen, 1980 
[54]
1/1/0 general surgery, 
urology, plastic & 
vascular
vomiting postoperatively 6 30/48
Zegveld, 1978 [55] 1/1/1 abdominal and 
others
after vomiting had occurred 6 34/58
Eberhart, unpublished 
data [5,16]
n/a various Any nausea, retching or vomiting for at least 5 
minutes
2,2 128/204 22,5 175/204
* time intervals were not exactly defined in the original paper and were judged according to additional information in the text, e.g. data on the length of stay in the recovery room, discharge times, etc.
Table 1: Success rates of placebo or no treatment after a first emetic episode postoperatively. (Continued)BMC Anesthesiology 2006, 6:14 http://www.biomedcentral.com/1471-2253/6/14
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and the upper bound of the 95%-confidence interval of
the pooled incidence of PONV recurrence. One of these
scenarios, the "best-case" scenario is of special interest. It
assumes a low rate of recurrent PONV after placebo/no
treatment. Taking the 24-hour pooled estimates of
patients suffering from an initial episode of PONV as an
example, this means that at least about 73% of the
patients can be expected to show recurrence of PONV. In
this case, one may argue that the incidence of PONV recur-
rence within the first 24 hours under any investigational
treatment of interest should be at least lower than 70%.
Discussion
As pointed out in the introduction the treatment of estab-
lished symptoms will remain a cornerstone of any strategy
aiming to decrease the sequelae for patients resulting from
postoperative nausea and vomiting despite the increasing
use of prediction models and guidelines for PONV-proph-
ylaxis. In short the main reasons are listed as follows:
- Prediction models for PONV for an individual patient
that are applicable in the clinical practice have by now not
turned out to be satisfactory [5,6]. Although the accuracy
can be increased to some extent using sophisticated statis-
tical methods [16], the main and limiting factor is the
absence of strong predictive parameters [22].
- A clinical decision whether or not to administer an
antiemetic measure is highly depended on the individual
characteristics of the patient and the clinical circum-
stances. For instance, in the outpatient setting antiemetic
prophylaxis is more often warranted than in inpatients. As
a consequence, guidelines did not and will probably never
define an exact threshold when antiemetic prophylaxis is
indicated [2].
- Computer simulations on the effectiveness and efficacy
of various antiemetic strategies have yielded no perfect
solution. Instead, it is suggested to develop individualized
standards at each institution depending on the composi-
tion of patient population [23].
The latter analysis further suggests that despite a liberal
antiemetic prophylaxis PONV will remain a "10–20%-
problem" in the postoperative period. Thus, studies on
the treatment of PONV are urgently warranted. However,
despite the need for such treatment studies it is very
unlikely that such trials – especially placebo controlled tri-
als – will be performed in the near future. Several reasons
have been described in the introduction section.
There are only two realistic solutions to deal with this lack
of sufficient data on antiemetic treatment.
Rates of recurrent vomiting are given on the y-axis depend- ing on the length of the observation period (x-axis) Figure 2
Rates of recurrent vomiting are given on the y-axis depend-
ing on the length of the observation period (x-axis). The area 
of the circles represent the number of patients included in 
the trial. Furthermore, light shading indicates studies with an 
Oxford (Jadad) score ≤ 3 whereas dark shading indicates a 
Jadad score of ≥ 4.
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One is that clinicians rely on the data that is available for
the prophylaxis of PONV and extrapolate these results to
the demands of treatment.
The other one is to fill this gap of evidence with data from
well conducted clinical trials. In the absence of a well
established (gold) standard treatment [15], one may stick
to the need of running placebo-controlled trials despite
their inherent difficulties. For this approach the calculated
estimate for the recurring incidence of PONV can be help-
ful to plan such a placebo-controlled study. For example,
using the 0–24 hour estimate of 84% (rate of recurring
PONV) and assuming a relative risk reduction by a certain
antiemetic treatment then the expected incidence in the
active treatment group would be 59% (= 0.84. [1-0.3]).
This absolute risk reduction of 25% points is a reasonable
margin for a clinically relevant effect and a sample size of
2 × 57 patients can be determined for two parallel groups
(placebo/antiemetic), a power of 80% and alpha (one-
sided) 2.5% for Fisher's exact test. Note, however, that
such a trial will of course be underpowered for smaller
effects that might be of some clinical relevance in the
absence of other evidence or in case the true incidence of
recurrent PONV is lower than predicted.
Instead of using a placebo comparator researchers may
think about using an active comparator and to compare
the effectiveness of these two verum groups with each
other or against a virtual margin based on the calculations
presented here. Note, however, that such a proceeding
comes at the price of not having demonstrated efficacy of
any of the treatments compared to placebo. This approach
addresses the special problem of placebo-control groups
within this special niche of research and makes use of
"historical" data of otherwise small trials that was pooled
using meta-analysis. Despite all legitimate criticisms not
to perform clinical trials without a placebo comparator,
there are some issues within this special area of research
that may justify the use of "historical" data. For the great
majority of antiemetic drugs efficacy and effectiveness has
been demonstrated in numerous prophylaxis trials with
PONV setting and other indications where nausea and
vomiting occur (e.g. radio- and chemotherapy for cancer).
There is no biological rationale why antiemetics should
not work postoperatively when their activity has been
proven intraoperatively. Furthermore, meta-analyses that
have been performed on the (few) placebo-controlled
treatment studies available have yielded results very simi-
lar to the numerous meta-analyses that have been per-
The pooled rate estimates and their 95%-confidence intervals  for the recurrence of PONV (dark shading) and vomiting  (light shading) within the different observation intervals Figure 3
The pooled rate estimates and their 95%-confidence intervals 
for the recurrence of PONV (dark shading) and vomiting 
(light shading) within the different observation intervals.
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Table 2: The pooled estimates and their 95%-confidence intervals of the recurrence of PONV or vomiting.
Observation interval Number of included studies* Incidence of recurrence of ... Pooled incidence (95%-confidence interval) [%]
0–1 hour 4 30,34,47,49 PONV 65 (53...75)
4 30,32,33,52 vomiting 67 (59...74)
0–2 hours 7 § PONV 67 (54...78)
5 29,37–39,45 PONV 69 (51...83)
831,38–40,42,44,48,51 vomiting 65 (44...81)
0–6 hours 928,30,36,38,40,46,50,51,55 PONV 79 (66...88)
10 28,30,32,36,38,40,41,46, vomiting 70 (58...79)
53,54
0–24 hours 13 § PONV 84 (73...91)
11 26,28,36,37,41,43–45,49, PONV 84 (71...92)
50,53 vomiting 79 (61...90)
8 26,28,35,36,41,42,44,53
* Please note that even if the absolute number of included trials is equal not necessarily the same trials were analyzed for the outcomes "PONV" on 
the one hand and "vomiting" on the other hand.
§ Pooled results using the random effects model with including the results of the two unpublished trials [5,16].BMC Anesthesiology 2006, 6:14 http://www.biomedcentral.com/1471-2253/6/14
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formed on the prophylaxis trials. Combined with the
difficulties related to placebo control groups within this
field and the ethical concerns of using placebo, one may
justify the use of empirical rate of recurrent PONV after
placebo or placebo/no treatment respectively for a single-
arm study planning. By summarizing the existing data
from an extensive literature search we can be confident
that PONV re-occurs in at least 50% of the cases within the
next 1–2 hours after a first event. Within the first 6 hours
after a first episode PONV occurs in about at least 65%
with no obvious further major increase (to 70–75%)
when the 24-hour observation interval is used instead.
Since these "best-case" scenario statements are based on
the lower 95% confidence interval bounds of the recur-
rent PONV rates, as a suggestion, any rate under
antiemetic treatment should be better than these margins.
This could mean that a similar 95%-confidence interval
for the recurrent PONV rate under an investigational
antiemetic intervention will not include such a "best-case"
scenario value.
Tramèr and colleagues argue in favour of the use of pla-
cebo-controlled PONV-trials. They performed a system-
atic review of efficacy trials investigating ondansetron for
the prophylaxis of PONV and found an enormous hetero-
geneity of the chance to develop nausea and vomiting
(control event rate). In part this heterogeneity was
assumed to be due to the random variation in small trials.
We also observed between-trial variability for the recur-
rence of PONV. A closer look at figure 1 (PONV), how-
ever, suggests that very few trials are responsible for the
variability. One trial comprises data from a Japanese
group whose results have been repeatedly questioned for
validity in the past [24,25]. However, since this study con-
tributes only 20 patients it has no relevant impact on the
global result of the analysis (e.g. estimate of PONV-recur-
rence after 24 hours observation period is 84% [95%-CI:
73%...91%] when the data of Fujii are included and 86%
[95%-CI: 76%...92%] when they are removed from the
meta-analysis). In the case of recurrent vomiting, again
the report of Fujii [26] and a second small trial with 12
patients reporting on the effectiveness of small doses of
propofol after gynaecological laparoscopy [27] might be
viewed as outlier.
Besides the limited between-study heterogeneity, the
inclusion of numerous small trials does not seem to
increase the between-heterogeneity which is in contrast to
other quantitative systematic reviews. In addition, the
absence of an obvious bias induced by a high or low
Jadad-score underlines the consistency of the analysis. The
same holds true for the inclusion or exclusion of the data
of the two observational studies where no placebo was
administered but simply "no treatment" was given to the
patients. Inclusion of both trials had a minor effect on the
estimates (see table 2). Finally, in agreement with the
expectations and as such another indicator of consistency
the rate estimates increase with enlarged follow-up peri-
ods with PONV rate estimates being always at least as fre-
quent as the estimates for vomiting.
Conclusion
The great majority of trials that investigated the rate of
recurrence of emetic symptoms after a placebo or placebo/
no treatment within the early postoperative period dem-
onstrate a consistently high incidence of emetic sequelae.
Conducting a systematic search of the literature and statis-
tical pooling of the available data using meta-analytic
techniques, more reliable estimate of these incidences of
recurrent symptoms can be determined. These numbers
can be used for defining a first guess clinically relevant
goal for future placebo controlled trials.
For several reasons, however, it is unlikely that rand-
omized controlled trials will be performed that help to fill
the gap between the huge knowledge that has accumu-
lated by a plethora of antiemetic trials investigating the
prophylaxis and the little knowledge on treatment of
established symptoms due to the paucity trials on the
treatment of PONV.
We conclude that the given estimates provide a solid
approximation to "real life" and can be used with some
confidence as a clue for future studies for instance in order
to perform power calculations. As a rule-of-thumb, for the
outcome "PONV" a recurrence rate of 65% can be used
during a early period 0–2 hours after administering a pla-
cebo and 80% for a longer observation interval (0–6
hours or 0–24 hours respectively). For the recurrence of
vomiting the expected incidences are 65% for the early
period and 70–75% for the extended interval.
Using the lower 95%-confidence intervals of these esti-
mates ("best-case" scenario) might be used as an indicator
to guide future study planning. Within this special area of
research, our data might even be used to come up with an
alternative to a placebo controlled study design. Thus,
research on antiemetic treatment which is urgently
required might be stimulated.
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